Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment

Human Psychopharmacology

Volumn 25, Issue 2, 2010, Pages 133-138

  Maayan, Lawrence A ^a,b,c   Vakhrusheva, Julia ^a  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NEW YORK UNIVERSITY CHILD STUDY CENTER   (United States)

Author keywords

Antipsychotic medication; Leptin; Metabolic; Pediatric; Psychotic disorders; Weight gain

Indexed keywords

AMPHETAMINE DERIVATIVE; CLONAZEPAM; ESCITALOPRAM; FLUVOXAMINE; GLUCOSE; HYDROCORTISONE; INSULIN; LEPTIN; LORAZEPAM; METHYLPHENIDATE; PROPRANOLOL; RISPERIDONE; SERTRALINE; TRIACYLGLYCEROL;

ADOLESCENT; ADOLESCENT DISEASE; ANTHROPOMETRY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY MASS; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HEART RATE; HORMONE BLOOD LEVEL; HUMAN; HYDROCORTISONE BLOOD LEVEL; INSULIN BLOOD LEVEL; LEPTIN BLOOD LEVEL; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PRIORITY JOURNAL; PSYCHOSIS; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO;

ADOLESCENT; ANTHROPOMETRY; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BODY MASS INDEX; BODY SIZE; BODY WEIGHT; CHILD; DAY CARE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; FEMALE; HIP; HUMANS; INSULIN RESISTANCE; LEPTIN; MALE; PILOT PROJECTS; PSYCHOTIC DISORDERS; RISPERIDONE; WAIST CIRCUMFERENCE; WEIGHT GAIN;

EID: 77749301838     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1097     Document Type: Article

References (43)

1. Amemiya S, Dobashi K, Urakami T, Sugihara S, Ohzeki T, Tajima N. 2007. Metabolic syndrome in youths. Pediatr Diabetes 8 (Suppl. 9): 48-54.
2. Arjona AA, Zhang SX, Adamson B, Wurtman RJ. 2004. An animal model of antipsychotic-induced weight gain. Behav Brain Res 152: 121-127.
3. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. 2001. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine haloperidol, or risperidone. J Clin Psychiatry 62: 231-238.
4. Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA. 2009. Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol 19: 101-109.
5. Citrome L, Vreeland B. 2008. Schizophrenia, obesity, and antipsychotic medications: what can we do? Postgrad Med 120: 18-33.
6. Cnop M, Landchild MJ, Vidal J, et al. 2002. The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51: 1005-1015.
7. Correll CU, Manu P, Olshanskiy V, Napolitano B, Kane JM, Malhotra AK. 2009. Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302: 1765-1773.
8. Esen-Danaci A, Sarandol A, Taneli F, Yurtsever F, Ozlen N. 2008. Effects of second generation antipsychotics on leptin and ghrelin. Prog Neuropsychopharmacol Biol Psychiatry 32: 1434-1438.
9. Fleischhaker C, Heiser P, Hennighausen K, et al. 2006. Clinical drug monitoring in child and adolescent psychiatry: side effects of atypical neuroleptics. J Child Adolesc Psychopharmacol 16: 308-316.
10. Fraguas D, Merchan-Naranjo J, Laita P, et al. 2008. Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatry 69: 1166-1175.
11. Freedman DS, Katzmarzyk PT, Dietz WH, Srinivasan SR, Berenson GS. 2009. Relation of body mass index and skinfold thicknesses to cardiovascular disease risk factors in children: the Bogalusa Heart Study. Am J Clin Nutr 90: 210-216.
12. Gothelf D, Falk B, Singer P, et al. 2002. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 159: 1055-1057.
13. Graham KA, Gu H, Lieberman JA, Harp JB, Perkins DO. 2005. Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. Am J Psychiatry 162: 1744-1746.
14. Gregoor JG, van der Weide J, Mulder H, et al. 2009. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol 29: 21-25.
15. Haupt DW, Luber A, Maeda J, Melson AK, Schweiger JA, Newcomer JW. 2005. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology 30: 184-191.
16. Jin H, Meyer JM, Mudaliar S, Jeste DV. 2008. Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin. Schizophr Res 100: 70-85.
17. Kang SG, Lee HJ, Park YM, et al. 2008. Possible association between the 2548A/G polymorphism of the leptin gene and olanzapine-induced weight gain. Prog Neuropsychopharmacol Biol Psychiatry 32: 160-163.
18. Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. 2005. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 115: e500-e503.
19. Kettaneh A, Heude B, Romon M, et al. 2007. High plasma leptin predicts an increase in subcutaneous adiposity in children and adults. Eur J Clin Nutr 61: 719-726.
20. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. 2007. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A 104: 3456-3459.
21. Kortelainen ML, Sarkioja T. 2001. Visceral fat and coronary pathology in male adolescents. Int J Obes Relat Metab Disord 25: 228-232.
22. Kroeze WK, Hufeisen SJ, Popadak BA, et al. 2003. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 28: 519-526.
23. Lieberman JA, Stroup TS, McEvoy JP, et al. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
24. Martin A, Scahill L, Anderson GM, et al. 2004. Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. Am J Psychiatry 161: 1125-1127.
25. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. 1985. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
26. Minocci A, Savia G, Lucantoni R, et al. 2000. Leptin plasma concentrations are dependent on body fat distribution in obese patients. Int J Obes Relat Metab Disord 24: 1139-1144.
27. Newcomer JW. 2005. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 19 (Suppl. 1): 1-93.
28. Park KG, Park KS, Kim MJ, et al. 2004. Relationship between serum adiponectin and leptin concentrations and body fat distribution. Diabetes Res Clin Pract 63: 135-142.
29. Pena R, Marquina D, Serrano A, et al. 2008. Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment. Schizophr Res 106: 315-319.
30. Penzner JB, Dudas M, Saito E, et al. 2009. Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 19: 563-573.
31. Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, et al. 2008. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J Clin Psychopharmacol 28: 289-295.
32. Reynolds GP, Hill MJ, Kirk SL. 2006. The 5-HT2C receptor and antipsychoticinduced weight gain - mechanisms and genetics. J Psychopharmacol. 20: 15-18.
33. Rodden AM, Diaz VA, Mainous AG 3rd, Koopman RJ, Geesey ME. 2007. Insulin resistance in adolescents. J Pediatr. 151: 275-279.
34. Roemmich JN, Rogol AD. 1999. Role of leptin during childhood growth and development. Endocrinol Metab Clin North Am 28: 749-764, viii.
35. Roemmich JN, Clark PA, Berr SS, et al. 1998. Gender differences in leptin levels during puberty are related to the subcutaneous fat depot and sex steroids. Am J Physiol 275: E543-E551.
36. Rutters F, Nieuwenhuizen AG, Verhoef SP, Lemmens SG, Vogels N, Westerterp-Plantenga MS. 2009. The relationship between leptin, gonadotropic hormones, and body composition during puberty in a Dutch children cohort. Eur J Endocrinol 160: 973-978.
37. Safer DJ. 2004. A comparison of risperidone-induced weight gain across the age span. J Clin Psychopharmacol 24: 429-436.
38. Sentissi O, Epelbaum J, Olie JP, Poirier MF. 2008. Leptin and ghrelin levels in patients with schizophrenia during different antipsychotics treatment: a review. Schizophr Bull 34: 1189-1199.
39. Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME. 2000. NIMH diagnostic interview schedule for children version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry 39: 28-38.
40. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. 2004. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 29: 133-145.
41. Weiss R, Dziura J, Burgert TS, et al. 2004. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 350: 2362-2374.
42. Woods SW, Martin A, Spector SG, McGlashan TH. 2002. Effects of development on olanzapine-associated adverse events. J Am Acad Child Adolesc Psychiatry 41: 1439-1446.
43. Zhang ZJ, Yao ZJ, Liu W, Fang Q, Reynolds GP. 2004. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. Magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 184: 58-62.